RESONANCE HEALTH LTD

Resonance Health’s 6.5% surge shows speculative hype, not proven tech—investors must scrutinize thin volume, missing earnings and regulatory risks before buying.

Resonance Health’s 6.49% surge sparks curiosity but remains a high‑risk bet—no revenue, thin liquidity, and unverified MRI tech at its core.

Resonance Health (RHT.AX) jumps 5.48 % as its non‑invasive MRI platform for hepatic iron overload gains investor traction and eyes regulatory approval, opening a multi‑billion diagnostic market.

Resonance Health shares surge 7% as the company announces a new MRI trial to detect liver fibrosis, promising safer, non‑invasive diagnostics.